jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Thyroid mass biopsy- Small 1cm

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

FNAC/biopsy for histopathology.

₹296₹423

30% OFF

Thyroid Mass Biopsy - Small 1cm Comprehensive Guide

  • Why is it done?
    • Test Purpose: Fine-needle aspiration cytology (FNAC) or core needle biopsy to obtain cellular material from a small thyroid nodule (approximately 1cm in size) for microscopic examination and cytopathologic diagnosis
    • Primary Indications: Evaluation of thyroid nodules with concerning sonographic features (irregular margins, hypoechogenicity, microcalcifications, increased vascularity); assessment of nodules with elevated TSH levels or suspicious clinical presentation; differentiation between benign and malignant thyroid lesions
    • Clinical Circumstances: Performed when ultrasound detects a thyroid nodule 1cm or larger with intermediate to high suspicion for malignancy; when thyroid function tests are abnormal; during follow-up of previously detected nodules showing growth or change in characteristics; when patient has risk factors for thyroid cancer (radiation exposure, family history, prior malignancy)
  • Normal Range
    • Bethesda System Classification: Results are categorized according to the Bethesda System for Reporting Thyroid Cytopathology into six categories
    • Category I - Non-Diagnostic: Insufficient cellular material; limited sample quality; cannot be further categorized (Risk of malignancy: 1-4%)
    • Category II - Benign: Consistent with benign conditions such as adenomatous goiter, colloid nodule, thyroiditis, or Hashimoto's disease; normal thyroid follicular cells with benign characteristics (Risk of malignancy: 0-3%)
    • Category III - Atypia of Undetermined Significance (AUS): Cytologic features that do not fit clearly into benign or malignant categories; follicular cells with nuclear enlargement or minimal hyperchromatic nuclei; may represent benign changes, follicular neoplasm, or early malignancy (Risk of malignancy: 5-15%)
    • Category IV - Follicular Neoplasm: Microfollicular architecture with increased cellularity; could represent follicular adenoma or follicular carcinoma; cannot distinguish on cytology alone (Risk of malignancy: 15-30%)
    • Category V - Suspicious for Malignancy: Cytologic features suspicious for malignancy but not diagnostic; significant nuclear abnormalities; may suggest papillary carcinoma, medullary carcinoma, or lymphoma (Risk of malignancy: 50-75%)
    • Category VI - Malignant: Definitive cytologic features of malignancy; papillary carcinoma, follicular carcinoma, medullary carcinoma, undifferentiated carcinoma, lymphoma, or other malignancies (Risk of malignancy: 97-99%)
    • Normal Result Interpretation: Category I-II results are considered favorable; suggest benign nature of nodule; typically require clinical correlation and ultrasound follow-up rather than immediate surgical intervention
  • Interpretation
    • Detailed Result Interpretation:
    • Non-Diagnostic (Category I): Indicates inadequate cellularity or specimen quality; does not provide diagnostic information; may require repeat biopsy with ultrasound guidance; consider rebiopsy if clinical suspicion remains high or nodule demonstrates growth on follow-up imaging
    • Benign (Category II): Strongly suggests benign nature of nodule; includes colloid adenomatous goiter, hyperplastic nodule, thyroiditis, cysts with colloid; low malignancy risk (0-3%); typically managed conservatively with clinical observation and ultrasound surveillance at 6-12 months, then annually if stable
    • Atypia of Undetermined Significance (Category III): Intermediate risk category (5-15% malignancy); represents borderline findings that cannot be definitively classified; management options include repeat biopsy, molecular testing (thyroid cancer panel, gene expression classifier), or diagnostic hemithyroidectomy in selected cases; clinical judgment and risk factors guide decision-making
    • Follicular Neoplasm (Category IV): Cannot differentiate between benign follicular adenoma and malignant follicular carcinoma on cytology alone; intermediate malignancy risk (15-30%); typically warrants surgical intervention (hemithyroidectomy or total thyroidectomy) for definitive histopathologic diagnosis; molecular testing may help stratify risk and guide surgical recommendations
    • Suspicious for Malignancy (Category V): High malignancy risk (50-75%); significant cytologic abnormalities suggesting malignancy but not diagnostic; typically indicates need for thyroidectomy; preoperative preparation including iodine supplementation if indicated; aggressive surgical approach usually recommended
    • Malignant (Category VI): Near-certain malignancy (97-99%); definitive cytologic features of cancer; demands surgical intervention; staging studies including CT neck, chest imaging, radioactive iodine scan for appropriate malignancy type; aggressive treatment approach including total thyroidectomy and lymph node dissection; consideration of radioactive iodine therapy, external beam radiation, or chemotherapy based on histology and staging
    • Factors Affecting Interpretation: Specimen adequacy and preparation quality; cellularity and cellular preservation; radiologist expertise; ultrasound characteristics of nodule; TSH level; patient risk factors (age, gender, radiation history, family history); nodule size and growth rate; concurrent thyroid disease; previous thyroid pathology or malignancy
    • Clinical Significance of Result Patterns: Benign findings in small nodules associated with excellent prognosis; AUS and follicular neoplasm categories benefit from molecular testing to stratify risk; combination of cytology with molecular markers improves diagnostic accuracy; growth on serial imaging increases concern regardless of cytology; presence of extrathyroidal extension on ultrasound elevates malignancy risk
  • Associated Organs
    • Primary Organ System: Thyroid gland (endocrine organ); component of hypothalamic-pituitary-thyroid (HPT) axis; involved in metabolic regulation, growth, and development
    • Benign Conditions Associated with Abnormal Results: Adenomatous goiter (multinodular goiter); colloid nodules; thyroid cysts; thyroiditis (Hashimoto's, subacute, silent); benign follicular adenomas; multinodular thyroid disease; iodine deficiency; hormonal influences from estrogen or pregnancy
    • Malignant Conditions Diagnosed: Papillary thyroid carcinoma (PTC - most common, 80%); follicular thyroid carcinoma (FTC); medullary thyroid carcinoma (MTC); anaplastic thyroid carcinoma (ATC - most aggressive); thyroid lymphoma; primary squamous cell carcinoma; undifferentiated carcinoma
    • Related Endocrine Conditions: Graves' disease; thyroid dysfunction (hypothyroidism, hyperthyroidism); thyroid hormone imbalance; secondary effects on pituitary and hypothalamus; metabolic complications from thyroid disease
    • Complications of Abnormal Results (Malignancy): Local invasion of surrounding structures (trachea, esophagus, laryngeal nerves causing voice changes); cervical lymph node metastases; distant metastases (lungs, bones, brain); thyroid hormone deficiency post-thyroidectomy requiring lifelong replacement therapy; hypoparathyroidism from parathyroid gland injury; recurrent laryngeal nerve injury causing hoarseness; superior vena cava syndrome from mass effect; spinal cord compression
    • Risk Factors for Malignancy: Radiation exposure (head, neck, chest radiation); male gender; age extremes (very young or >45 years); rapid nodule growth; family history of thyroid cancer; prior thyroid cancer; hereditary cancer syndromes (familial adenomatous polyposis, Cowden syndrome); immunosuppression; underlying thyroid disease; certain genetic mutations (RET/PTC, BRAF V600E)
  • Follow-up Tests
    • Follow-up Based on Benign Results (Category I-II): Ultrasound surveillance at 6-12 months following biopsy; if stable, repeat ultrasound annually for 2 years, then as clinically indicated; TSH level assessment and thyroid function panel; thyroid antibodies if autoimmune thyroiditis suspected; repeat biopsy only if nodule enlarges or develops new concerning ultrasound features
    • Follow-up Based on AUS (Category III): Repeat ultrasound-guided biopsy in 3-6 months; thyroid molecular testing panel (ThyroSeq, ThyGenX, Afirma GSC) to assess malignancy risk; gene expression classifier to stratify risk; TSH suppression with levothyroxine in selected cases; close clinical correlation with nodule characteristics; hemithyroidectomy if molecular markers indicate high risk; conservative management with surveillance if molecular testing reassuring
    • Follow-up Based on Follicular Neoplasm (Category IV): Thyroid molecular testing to risk-stratify (mutations in BRAF, RAS, TP53, PTEN); comprehensive genetic analysis; hemithyroidectomy (diagnostic thyroid lobectomy) for definitive histopathologic diagnosis; TSH-stimulated thyroglobulin testing if history suggestive of malignancy; radioactive iodine uptake scan may be performed post-operatively; completion thyroidectomy if intraoperative frozen section shows carcinoma
    • Follow-up Based on Suspicious for Malignancy (Category V): Total thyroidectomy (near-total or total) with central compartment lymph node dissection consideration; preoperative ultrasound of neck for lymph node evaluation; CT chest/neck for staging if clinically indicated; TSH suppressive therapy post-operatively; radioactive iodine ablation if indicated based on histology; TSH-stimulated thyroglobulin measurement; long-term TSH suppression therapy; regular clinical follow-up
    • Follow-up Based on Malignant Results (Category VI): Immediate surgical oncology consultation; comprehensive staging studies including CT neck/chest, MRI as indicated, PET-CT if anaplastic carcinoma; total thyroidectomy with bilateral lymph node dissection; consideration of modified radical neck dissection if positive nodes; radioactive iodine therapy post-operatively; thyroid hormone suppressive therapy; TSH-stimulated thyroglobulin monitoring; external beam radiation therapy if indicated; chemotherapy consultation for aggressive histologies; multidisciplinary team management
    • Related Tests and Monitoring: Thyroid-stimulating hormone (TSH); free T4 level; thyroid peroxidase (TPO) antibodies; thyroglobulin antibodies; calcitonin level (for medullary carcinoma screening); complete blood count; metabolic panel; serial neck ultrasound imaging; radioactive iodine scan when indicated; thyroglobulin surveillance in follow-up period; genetic testing for RET mutation if family history of medullary carcinoma
    • Long-term Monitoring Strategy: Benign nodules: annual ultrasound for 2-3 years, then as clinically indicated; AUS/follicular: intermediate follow-up with repeat imaging and possible biopsy; malignant: lifelong surveillance with clinical examination, ultrasound, thyroglobulin monitoring; endocrinology co-management for hormone replacement and TSH suppression goals; individualized monitoring based on histology, stage, and risk factors
  • Fasting Required?
    • Fasting Requirement: No - Fasting is NOT required for thyroid mass biopsy
    • Pre-Procedure Medications: Continue routine medications including thyroid replacement therapy (levothyroxine); patients on anticoagulation (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel) should discuss with proceduralist; typically continue aspirin, may discontinue warfarin 5-7 days prior or bridge with heparin; hold NSAIDs 3-5 days prior to minimize bleeding risk; alert provider to bleeding disorders or use of anticoagulants before procedure
    • Patient Preparation Requirements: Arrive 10-15 minutes early for registration; wear comfortable, loose-fitting clothing with front-opening top or gown; remove jewelry from neck/chest area; may have light breakfast on morning of procedure; arrange for transportation if sedation used (rare); inform team of allergies, especially iodine or contrast; disclose all medications and supplements
    • Pre-Procedure Instructions: Nothing to avoid eating or drinking; nothing to avoid taking by mouth; no special bowel preparation needed; may take routine medications with small sip of water; continue normal daily routine; bring insurance cards and photo ID; bring list of current medications; have pre-procedure ultrasound images available if performed elsewhere
    • Procedural Notes: Usually performed as outpatient with ultrasound guidance; local anesthesia (lidocaine) infiltrated at biopsy site; patient positioned supine with neck extended; procedure time typically 15-30 minutes; minimal pain with local anesthesia; can return to normal activities immediately post-procedure; no post-operative restrictions; mild neck soreness common; ice pack application for comfort recommended; monitor for signs of infection or excessive bleeding
    • Post-Procedure Care: Apply ice to neck for first 24 hours to minimize swelling; neck bandage usually removed within 24 hours; can eat and drink immediately post-procedure; may resume normal activities including light exercise; avoid strenuous activity or heavy lifting for 24-48 hours; expect mild bruising or swelling that resolves in several days; apply warm compress after 48 hours if helpful; acetaminophen acceptable for pain; contact provider if significant swelling, bleeding, difficulty swallowing, or signs of infection develop

How our test process works!

customers
customers